Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
Allograft dendritic cell (DC) content has been identified as a predictor of relapse and event-free survival after allogeneic bone marrow transplantation. However, the prognostic importance of DCs has not been evaluated in the setting of autologous hematopoietic stem cell transplantation (HSCT). We prospectively determined pre-transplant and post transplant DC levels, including DC1 and DC2 subset levels, in 53 patients with diffuse large B-cell non-Hodgkin's lymphoma (DLBC NHL) undergoing autologous HSCT. Pre-transplant DCs were measured in the collected stem cell products and were therefore indicative of cell numbers infused directly into patients; post transplant analysis of DCs was performed on the peripheral blood of patients 6 weeks after the infusion of autologous stem cells. Higher pre-transplant levels of DC1 cells and total DCs were significantly associated with improved survival. Similarly, greater post transplant levels of total DCs and both subsets were significantly associated with survival. These findings suggest a relationship between DC reconstitution and survival following autologous HSCT for DLBC NHL. Strategies to increase autograft DC content or accelerate DC recovery after autologous HSCT might improve outcomes in this setting.
Dean
R
R
Department of Hematology and Medical Oncology, Bone Morrow Trasplant Program, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Masci
P
P
Pohlman
B
B
Andresen
S
S
Serafino
S
S
Sobecks
R
R
Kuczkowski
E
E
Curtis
J
J
Maciejewski
J
J
Rybicki
L
L
Kalaycio
M
M
Hsi
E
E
Theil
K
K
Bolwell
B J
BJ
D000328:Adult; D000368:Aged; D001854:Bone Marrow Cells / Q000166:cytology; D016026:Bone Marrow Transplantation; D049109:Cell Proliferation; D017690:Cell Transplantation; D003713:Dendritic Cells / Q000166:cytology*; D005260:Female; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008223:Lymphoma; D016393:Lymphoma, B-Cell / Q000401:mortality* / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000166:cytology; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D016179:Granulocyte Colony-Stimulating Factor